Applied Therapeutics, Inc.
APLT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for APLT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Sep 30, 2025.
Tracking 1 pipeline candidate · 10 clinical trials for Applied Therapeutics, Inc..
Run Applied Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Applied Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
2.9 months
OCF -$18M · Net income -$19M
Lead: Phase 2/Phase 3
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is Applied Therapeutics, Inc.'s lead drug candidate?
Applied Therapeutics, Inc.'s most advanced tracked candidate is AT-003 (Phase 2/Phase 3) for Treatment of diabetic retinopathy (DR).
Who is the CEO of Applied Therapeutics, Inc.?
Interim Chief Executive is the chief executive officer of Applied Therapeutics, Inc. (APLT).
Where is Applied Therapeutics, Inc. headquartered?
Applied Therapeutics, Inc. (APLT) is headquartered in New York, NY, United States.
What therapeutic areas does Applied Therapeutics, Inc. focus on?
Applied Therapeutics, Inc. develops therapies across Oncology, Rare Disease, Neurology, Ophthalmology, Cardiovascular, Infectious Disease, Respiratory, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.